Slide 1: Full Year 2020 Results
Full Year 2020 Results Matthias Gaertner CEO/CFO March 31, 2021
Slide 2: Executive summary, Financial overview, Guidance 2021, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 2
Slide 3: Highlights 2020 until year-to-date – Growth strategy on track
Executive summary Highlights 2020 until year-to-date – Growth strategy on track Significant progress in strategy implementation – major decisions for future growth • Attractive growth potentials through acquisitions: • Cranach Pharma GmbH – specialized pharmaceutical wholesaler (Jan 21) • Kölsche Bl
Slide 4: Game-changing acquisitions in 2020
Executive summary Game-changing acquisitions in 2020 Acquisition of Cranach Pharma GmbH Acquisition of Kölsche Blister GmbH • HQ in Hamburg, Germany with activities across • HQ in Cologne, Germany with activities across Germany Germany • Well established wholesale of specialty pharma • Well establis
Slide 5: Dynamic growth despite COVID-19 pandemic: business model intact
Executive summary Dynamic growth despite COVID-19 pandemic: business model intact Revenue €m EBITDA pre¹ €m EBT pre¹ €m • First quarter saw extensive stockpiling of pharmaceuticals • March 2020: Introduction of an order – quota system – by the Federal Institute for Drugs and Medical Devices (BfArM)
Slide 6: Quarterly recovery after Q2 2020 Corona-related revenue & sales decline
Executive summary Quarterly recovery after Q2 2020 Corona-related revenue & sales decline Revenue €m EBITDA pre¹ €m EBT pre¹ €m 173.6 4.8 162.8 160.0 4.3 4.0 3.8 3.7 130.1 3.1 2.2 1.2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2020 2020 ¹ EBITDA and EBT without extraordinary expenses: adjusted for ext
Slide 7: Proven growth strategy in place to maintain Medios' leading position
Executive summary Proven growth strategy in place to maintain Medios’ leading position as a provider of specialty pharma solutions in Germany VERTICAL GROWTH DRIVER HORIZONTAL GROWTH DRIVER PROFITABILITY DRIVER Extend product Grow customer Leverage range and expand base and economies of to further p
Slide 8: ESG strategy well under way
Sustainability ESG strategy well under way • Code of conduct published end of 2020 • Implementation of ESG targets in the compensation system of the Executive Board • For the first time publication of • Develop and establish ESG strategy, focus on: “voluntary report” based on CSR-RUG¹ • Environmenta
Slide 9: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 9
Slide 10: FY 2020 – Solid Group Financials despite COVID-19 pandemic
Financial overview FY 2020 – Solid Group Financials despite COVID-19 pandemic In € million FY 2020 FY 2019 ∆% Revenue 626.5 516.8 21.2 • Strong revenue growth, Pharmaceutical COGS¹ 589.3 483.4 Supply key contributor ratio in % of revenue 94.1 93.5 21.9 • Kölsche Blister included in revenue with Pers
Slide 11: FY 2020 Segments – Growth driven by wholesale business
Financial overview FY 2020 Segments – Growth driven by wholesale business Patient-specific Internal Services and Pharmaceutical Supply Group Therapies IFRS consolidation In € million FY 2020 FY 2019 FY 2020 FY 2019 FY 2020 FY 2019 FY 2020 FY 2019 Revenue (total) 596.9 491.8 66.3 57.0 -36.6 -31.9 626
Slide 12: Financing power – strong financial position to invest in future growth
Financial overview Financing power- strong financial position to invest in future growth As of 31 December 2020 In € million Syndicated loan 62.5 Organic growth Thereof called -1.5 • Up to €10 million to be invested in new labs Cash & cash equivalents 19.8 External growth • M&A strategy: focus on co
Slide 13: Guidance 2021
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 13
Slide 14: Forecast – Nearly doubling of revenue and jump in earnings
Guidance 2021 Forecast – Nearly doubling of revenue and jump in earnings In € million 2021F¹ 2020 Growth % Group revenue 1,150 – 1,200 626.0 84 – 92 + External growth will be substantially driven by the acquisitions of Cranach Pharma, and Kölsche Blister; additional acquisitions EBITDA pre² 38 – 39
Slide 15: Proven financial track with strong profitable growth
Key financials Proven financial track with strong profitable growth Medios Group IFRS 20161 20172 20182 20192 20202 2021E2 1,150- Pharmaceutical Supply 1,200 Patient-specific Therapies 627 517 10% 10% 328 254 160 12% 90% ++++ 17% 90% 25% 88% 83% Revenue in €m 75% 31-32 Pharmaceutical Supply Patient-
Slide 16: Organic growth – Diverse attractive approaches
Guidance 2021 Organic growth – Diverse attractive approaches • Expansion of manufacturing capacities – completion of new laboratories in Berlin • Further establishment of “blistering“ in Germany • Expansion of partner network of specialized pharmacies • Preparation of e-prescriptions - launch on 1 J
Slide 17: Inorganic growth: Medios is playing an active role in consolidation
Growth strategy Inorganic growth: Medios is playing an active role in the ongoing consolidation process Types of potential target companies Premium Premium 1 patient-specific manufacturers 2 pharmaceutical suppliers Innovation / 3 process optimization 1 • Play an active role in the 2 • Increase scal
Slide 18: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 18
Slide 19: Consolidated statement of comprehensive income
Appendix Consolidated statement of comprehensive income In € thousand FY 2020 FY 2019 Q4 2020 Q4 2019 Revenue 626,543 516,805 173,644 145,126 Change in stocks of finished goods and -7 42 -52 -420 work-in-progress Work performed and capitalized 352 550 334 453 Other income 468 1,254 181 62 Cost of ma
Slide 20: Consolidated balance sheets FY 2020
Appendix Consolidated balance sheets FY 2020 Assets In € thousand FY 2020 FY 2019 Liabilities In € thousand FY 2020 FY 2019 Non-current assets 58,232 37,136 Equity Intangible assets 35,237 31,260 Subscribed capital 16,085 14,564 Capital reserves 104,487 51,273 Property, plant and 5,337 2,549 Accumul
Slide 21: Consolidated cash flow statement FY/Q4 2020 (1/2)
Appendix Consolidated cash flow statement FY/Q4 2020 (1/2) In € thousand FY 2020 FY 2019 Q4 2020 Q4 2019 Cash flow from operating activities Net income for the year 6,064 9,760 1,794 1,801 Depreciation and amortization on non-current assets 3,551 1,982 982 359 Decrease/increase in provisions 11 126
Slide 22: Consolidated cash flow statement FY/Q4 2020 (2/2)
Appendix Consolidated cash flow statement FY/Q4 2020 (2/2) In € thousand FY 2020 FY 2019 Q4 2020 Q4 2019 Cash flow from investment activities Payments made for investments in intangible assets -2,142 -1,215 -939 281 Payments made for investments in property, plant and equipment -2,720 -874 -783 -64
Slide 23: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations Phone +49 30 232 566 800 ir@medios.ag 23
Slide 24: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 25: Full Year Presentation
Full Year Presentation Matthias Gaertner CEO/CFO March 31, 2021